Silymarine during maintenance therapy of acute promyelocytic leukemia. 1993

R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari

UI MeSH Term Description Entries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012838 Silymarin A mixture of flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum. It consists primarily of silybin and its isomers, silicristin and silidianin. Silymarin displays antioxidant and membrane stabilizing activity. It protects various tissues and organs against chemical injury, and shows potential as an antihepatoxic agent. Carsil,Karsil,Legalon,Silimarin
D015473 Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION. Leukemia, Myeloid, Acute, M3,Leukemia, Progranulocytic,Myeloid Leukemia, Acute, M3,Progranulocytic Leukemia,Promyelocytic Leukemia, Acute,AML M3,Acute Promyelocytic Leukemia,Leukemia, Acute Promyelocytic,M3 ANLL,ANLL, M3,Acute Promyelocytic Leukemias

Related Publications

R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
January 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
August 2012, Journal of the National Comprehensive Cancer Network : JNCCN,
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
April 2023, Cureus,
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
January 2004, Advances in pharmacology (San Diego, Calif.),
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
April 1987, Cancer,
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
June 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
April 2011, Haematologica,
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
October 1993, Leukemia,
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
November 2010, Fertility and sterility,
R Invernizzi, and S Bernuzzi, and D Ciani, and E Ascari
March 2007, American journal of hematology,
Copied contents to your clipboard!